Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer

Gynecologic Oncology

Volumn 108, Issue 1, 2008, Pages 68-71

  Ramirez, Pedro T ^a   Landen Jr , Charles N ^a   Coleman, Robert L ^a   Milam, Michael R ^a   Levenback, Charles ^a   Johnston, Taren A ^a   Gershenson, David M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bortezomib; Phase I trial in ovarian cancer; Proteasome inhibitor

Indexed keywords

BORTEZOMIB; CARBOPLATIN; PLATINUM DERIVATIVE; PROTEASOME INHIBITOR; TAXANE DERIVATIVE;

ADULT; AGE DISTRIBUTION; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; HUMAN; NAUSEA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYNCOPE; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CARBOPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES;

EID: 37349084533     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.08.071     Document Type: Article

References (12)

1. American Cancer Society. Cancer statistics (2007). http://www.acs.org
2. Markman M., Rothman R., Hakes T., et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9 (1991) 389-393
3. Vermorken J.B., Eisenhauer EA., Lu F., et al. Prognostic features of importance for phase II studies in platinum-pretreated ovarian cancer patients, abstract. Proceedings of the 6th International Congress on Anticancer Treatment, Paris (1996) 130
4. Mimnaugh E.G., Yunmbam M.K., Li Q., et al. Prevention of cisplatin-DNA adduct repair and potentiation of cisplatin-induced apoptosis in ovarian carcinoma cells by proteasome inhibitors. Biochem Pharmacol 60 (2000) 1343-1354
5. An W.G., Hwang S.G., Trepel J.B., et al. Protease inhibitor-induced apoptosis: accumulation of wt 53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 14 (2000) 1276-1283
6. Kalogeris T.J., Larous F.S., Cockrell A., et al. Effect of selective proteasome inhibitors on TNF-induced activation of primary and transformed endothelial cells. Am J Physiol 276 (1999) C856-C864
7. Palombella V.J., Rando O.J., Goldberg A.L., et al. T. The ubiquitin-proteasome pathway is required for processing the NF-kB1 precursor protein and the activation of NF-kB. Cell 78 (1994) 773-785
8. Aghajanian C., Soignet S., Dizon D.S., et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8 (2002) 2505-2511
9. Huang T.T., Wuerzberger-Davis S.M., Seufzer B.J., et al. NF-kB activation by a camptothecin. J Biol Chem 275 (2000) 9501-9509
10. Yan X.J., Rosales N., Aghajanian C., et al. Cisplatin induces NF-kB activity through IkB kinase dependent pathway. Proc Am Assoc Cancer Res 40 (1999) 195 [abstract 1299]
11. Yunmbam M.K., Li Q.Q., Mimnaugh E.G., et al. Effect of the proteasome inhibitor ALLnL on cisplatin sensitivity in human ovarian tumor cells. Int J Oncol 19 (2001) 741-748
12. Aghajanian C., Dizon D.S., Sabbatini P., et al. Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J Clin Oncol 23 (2005) 5943-5949